Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Von Willebrand factor.

Zaverio M Ruggeri1

  • 1Room Research Laboratory for Arteriosclerosis and Thrombosis, Division of Experimental Hemostasis and Thrombosis, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA. ruggeri@scripps.edu

Current Opinion in Hematology
|February 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human PAR1 expressed on mouse platelets contributes to hemostasis and arterial occlusion.

bioRxiv : the preprint server for biology·2025
Same author

GPIbα-filamin A interaction regulates megakaryocyte localization and budding during platelet biogenesis.

Blood·2023
Same author

Platelet glycoprotein V spatio-temporally controls fibrin formation.

Nature cardiovascular research·2023
Same author

Inflammatory platelet production stimulated by tyrosyl-tRNA synthetase mimicking viral infection.

Proceedings of the National Academy of Sciences of the United States of America·2022
Same author

Arenaviral infection causes bleeding in mice due to reduced serotonin release from platelets.

Science signaling·2022
Same author

The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.

Haematologica·2022
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Recent advances reveal how von Willebrand factor’s structure changes influence platelet binding, aiding thrombus formation. Understanding these mechanisms is key for developing targeted arterial thrombosis therapies.

Area of Science:

  • Vascular Biology and Pathology
  • Biochemistry
  • Hemostasis and Thrombosis

Background:

  • Von Willebrand factor (vWF) is a key adhesive protein in platelet function and thrombus formation at vascular injury sites.
  • Recent research has significantly advanced the understanding of vWF's biological properties.

Purpose of the Study:

  • To elucidate the structural and functional properties of vWF, particularly its A1 domain and interaction with glycoprotein Ibalpha.
  • To detail vWF's interaction with tissues and platelets under hemodynamic forces.
  • To explore the link between vWF multimer size regulation and microvascular thrombosis.

Main Methods:

  • Structural analysis of vWF domains, focusing on conformational changes in the A1 domain.
  • Functional studies of the vWF A1 domain and glycoprotein Ibalpha interaction.

Related Experiment Videos

  • Investigation of vWF multimer size regulation in microvascular thrombosis.

    • Main Results:

    • Specific conformational changes in the vWF A1 domain, driven by single amino acid substitutions, enhance platelet binding.
    • Detailed elucidation of the structural and functional aspects of the vWF A1 domain-glycoprotein Ibalpha interaction.
    • New findings link vWF multimer size regulation to microvascular thrombosis.

    Conclusions:

    • Progress in understanding vWF structure and function provides critical insights into its role in vascular biology and pathology.
    • Detailed knowledge of vWF-platelet interactions under flow conditions may guide the development of novel anti-thrombotic therapies.
    • Understanding vWF regulation is crucial for addressing arterial and microvascular thrombosis.